AEM vs BAK

AEM's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability, while the absence of an Altman Z-Score limits distress risk assessment. Despite strong profitability metrics—ROE of 15.67%, gross margin of 70.24%, and robust earnings growth of 85.8% YoY—the stock trades at a premium valuation (P/E 31.23 vs sector avg 25.89) above both the Graham Number ($85.07) and intrinsic value estimate ($202.66). Strong recent price performance (+145% 1Y) and analyst buy recommendation are counterbalanced by weak technical trend (10/100) and limited insider sentiment (40/100). The balance between operational strength and valuation concerns leads to a neutral stance.

BAK exhibits severe financial distress, as evidenced by a Piotroski F-Score of 1/9, indicating extreme weakness in operational and financial health. The absence of an Altman Z-Score and the company's negative profitability metrics—such as a -7.11% profit margin, -9.65% operating margin, and -2.76% ROA—underscore deteriorating fundamentals. Despite a recent 14.9% 1-year return, the stock has declined 61.9% over five years, reflecting persistent underperformance. The negative forward P/E of -2.25 and Price/Book of -5.01 signal deep value traps, while the lack of dividend and weak insider sentiment further erode confidence. Analysts maintain a 'hold' recommendation, reflecting cautious optimism amid structural challenges.